Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma

Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific targeting, the concentration of the drug in tumor tissue cannot be permanently maintained at a level that i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Deliv
Autors principals: Tang, Xiaolong, Chen, Longzhou, Li, Amin, Cai, Shiyu, Zhang, Yinci, Liu, Xueke, Jiang, Zhenyou, Liu, Xinkuang, Liang, Yong, Ma, Dong
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058710/
https://ncbi.nlm.nih.gov/pubmed/29916268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2018.1477859
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars